Ester Zapotocka

Ester Zapotocka

Auto-generated profile, based on publicly available information

Ester Zapotocka

Department of Pediatric Hematology/Oncology University Hospital Motol Prague Czech Republic

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in The Lancet Haematology
Verified
Journal Article
Open access
AAAndishe Attarbaschi
Andishe Attarbaschi
EBEdit Bardi
Edit Bardi
SBShlomit Barzilai-Birenboim
Shlomit Barzilai-Birenboim
DBDeepa Bhojwani
Deepa Bhojwani
MHMelanie M Hagleitner
Melanie M Hagleitner
EZEster Zapotocka
Ester Zapotocka
5-year overall survival rates have surpassed 90% for childhood acute lymphocytic leukaemia, but survivors are at risk for permanent health sequelae. Although event-free survival appropriately represents the outcome for cancers with poor overall survival, this metric is inadequate when cure rates are high but challenged by serious, persistent complications. Accordingly, a group of experts in paediatric haematology-oncology, representative of 17 international acute lymphocytic leukaemia study groups, launched an initiative to construct a measure, designated severe toxicity-free survival (STFS), to quantify the occurrence of physician-prioritised toxicities to be integrated with standard cancer outcome reporting. Five generic inclusion criteria (not present before cancer diagnosis, symptomatic, objectifiable, of unacceptable severity, permanent, or requiring unacceptable treatments) were used to assess 855 health conditions, which resulted in inclusion of 21 severe toxicities. Consensus definitions were reached through a modified Delphi process supplemented by two additional plenary meetings. The 21 severe toxicities include severe adverse health conditions that substantially affect activities of daily living and are refractory to therapy (eg, refractory seizures), are without therapeutic options (eg, blindness), or require substantially invasive treatment (eg, cardiac transplantation). Incorporation of STFS assessment into clinical trials has the potential to improve and diversify treatment strategies, focusing not only on traditional outcome events and overall survival but also the frequencies of the most severe toxicities. The two major aims of this Review were to: prioritise and define unacceptable long-term toxicity for patients with childhood acute lymphocytic leukaemia, and define how these toxicities should be combined into a composite quantity to be integrated with other reported outcomes. Although STFS quantifies the clinically unacceptable health tradeoff for cure using childhood acute lymphocytic leukaemia as a model disease, the prioritised severe toxicities are based on generic considerations of relevance to any other cancer diagnosis and age group.

24 April 2025 in Haemophilia
Verified
Journal Article
Open access
ABAngelika Batorova
Angelika Batorova
ABAtanas Banchev
Atanas Banchev
ABAna Boban
Ana Boban
BBBrigitte Brand
Brigitte Brand
MBMelen Brinza
Melen Brinza
EZEster Zapotocka
Ester Zapotocka
Background: Physical activity is now considered generally beneficial for persons with haemophilia (PWH). However, the specific type and extent of activity and its impact on quality of life (QoL) and bleed protection during exercise is under‐researched. This knowledge gap should significantly impact PWH's ability to manage their condition optimally. Objective: To explore levels of physical activity and understand bleed protection during exercise among PWH as part of the Liberate Life project. Methods: A web‐based survey was conducted across eight European countries between August and September 2023. The online survey was developed by haemophilia treatment experts and patient association representatives according to the Checklist for Reporting Results of Internet E‐Surveys (CHERRIES) method. The 24‐question survey, distributed to PWH or their parents/caregivers, covered topics such as demographics, the impact of haemophilia on daily life, bleed protection understanding and involvement in physical activities. An activity index was used to categorize PWH as ‘more’ or ‘less’ active. Results: Of 374 respondents analysed, PWH engagement in physical activities, mainly low‐impact activities like walking, swimming or cycling, was high (90.9%). Most respondents (74.9%) were ‘less active’ according to the activity index. There was a significant knowledge gap in respondents' understanding of bleed protection provided by factor and non‐factor therapies. Joint health (68.7%), disease severity (69.3%) and capability for physical activity (62.3%) were indicated as key variables influencing PWH QoL. Conclusion: These findings underscore the need for educational programs to improve PWH's understanding of protective factor levels and the role of non‐factor therapies in managing haemophilia.

13 October 2026 in Blood Vessels, Thrombosis & Hemostasis
Verified
Journal Article
Open access
AJAkshat Jain
Akshat Jain
CLCindy Leissinger
Cindy Leissinger
VVVladimir Vdovin
Vladimir Vdovin
PZPavel Zharkov
Pavel Zharkov
LDLeonid Dubey
Leonid Dubey
RSRobert F. Sidonio
Robert F. Sidonio